Ramm Pharma (TSE:RAMM)
:RAMM
RAMM Stock Chart & Stats
C$0.06
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.06
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.25
Previous CloseN/A
Volume0.00
Average Volume (3M)118.29K
Market Cap
C$2.39M
Enterprise ValueC$1.46M
Total Cash (Recent Filing)C$985.37K
Total Debt (Recent Filing)C$61.30K
Price to Earnings (P/E)―
Beta-2.15
Next Earnings
Jun 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding119,389,320
10 Day Avg. Volume262,784
30 Day Avg. Volume118,288
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.53
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA near-zero debt load materially reduces interest burden and refinancing risk, giving management time and flexibility to execute restructuring or strategic options. Over a 2–6 month horizon this conservatism preserves optionality to raise capital or pursue partnerships without immediate solvency pressure.
Improving Cash Burn TrendAlthough still negative, recent improvement in operating and free cash flow indicates the company is reducing cash burn compared with 2022–2024. This trend, if sustained, lowers near-term external financing needs and increases the probability management can stabilize operations without constant capital raises.
Industry: Specialty & Generic DrugsOperating in the specialty and generic drug segment provides durable demand driven by ongoing medication needs and potential for recurring revenue. Structural industry dynamics can support steady product demand and licensing or contract-manufacturing opportunities over the medium term.
Bears Say
Sharply Declining RevenueSustained and material revenue contraction undermines scale economics and makes fixed-cost recovery harder. Over a multi-month horizon, falling top-line reduces ability to invest in R&D or commercialization, exacerbates margin pressure, and increases reliance on external funding to sustain operations.
Severe Profitability ShortfallVery large negative EBIT and net margins reflect persistent operating losses and an unprofitable cost structure. This prevents internal cash generation, forces dependence on financing, and indicates the business model has not yet reached a sustainable margin profile absent major operational changes or revenue recovery.
Eroded Equity And Cash CushionSubstantial erosion of equity and a deeply negative ROE signal limited balance-sheet resilience. With a shrunken equity base, the company has less capacity to absorb further losses and may face tougher terms raising capital, increasing the risk that sustained losses threaten long-term viability without corrective action.
Ramm Pharma News
RAMM FAQ
What was Ramm Pharma’s price range in the past 12 months?
Ramm Pharma lowest stock price was C$0.01 and its highest was C$0.25 in the past 12 months.
What is Ramm Pharma’s market cap?
Ramm Pharma’s market cap is C$2.39M.
When is Ramm Pharma’s upcoming earnings report date?
Ramm Pharma’s upcoming earnings report date is Jun 30, 2026 which is in 83 days.
How were Ramm Pharma’s earnings last quarter?
Currently, no data Available
Is Ramm Pharma overvalued?
According to Wall Street analysts Ramm Pharma’s price is currently Overvalued.
Does Ramm Pharma pay dividends?
Ramm Pharma does not currently pay dividends.
What is Ramm Pharma’s EPS estimate?
Ramm Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ramm Pharma have?
Ramm Pharma has 119,389,320 shares outstanding.
What happened to Ramm Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ramm Pharma?
Currently, no hedge funds are holding shares in TSE:RAMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ramm Pharma
RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.
Technical Analysis
Options Prices
Currently, No data available
---